Why consider treatment in China for Idiopathic Pulmonary Fibrosis?

China offers advanced IPF care at leading hospitals with experienced pulmonologists and thoracic surgeons who specialize in antifibrotic therapy and lung transplantation. Treatment costs are significantly lower than in Western countries—often 30–50% less—while maintaining high standards of care. Patients also benefit from access to cutting-edge diagnostic tools, such as high-resolution CT and pulmonary function testing, and streamlined transplant evaluation processes at accredited centers.